Dapagliflozin in Patients with Chronic Kidney Disease
Abstract
This randomized controlled trial (DAPA-CKD) evaluated the efficacy of dapagliflozin. a sodium-glucose cotransporter 2 (SGLT2) inhibitor in reducing renal and cardiovascular outcomes among 4304 patients with chronic kidney disease (CKD), with or without type 2 diabetes. Over a median follow-up of 2.4 years, dapagliflozin significantly reduced the risk of the primary composite endpoint: sustained decline in estimated glomerular filtration rate (GFR) ≥50%, progression to end-stage kidney disease, or death from renal or cardiovascular causes (HR: 0.61; P<0.001). Benefits were also seen in renal-specific outcomes, cardiovascular mortality and heart failure hospitalization, and all-cause mortality. The treatment effect was consistent regardless of diabetes status. Safety data showed no increased risk of diabetic ketoacidosis, hypoglycemia in nondiabetics, or other serious adverse events. The trial supports dapagliflozin’s kidney- and cardioprotective role in CKD management beyond its glucose-lowering effects
Keywords:
dapagliflozin
chronic kidney disease
SGLT2 inhibitors
renal outcomes
cardiovascular death
eGFR decline
heart failure
end-stage kidney disease
Article Document
1 / 1
100%